We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Developing High Content Imaging Assays for Chronic Kidney Disease

Developing High Content Imaging Assays for Chronic Kidney Disease content piece image

Chronic Kidney Disease (CKD) is a progressive disease characterized by damage to the glomerular filtration barrier (GFB), the loss of larger and essential proteins from the blood into the urine (proteinuria), causing considerable damage to the kidney tubules. Podocytes form the size-selective sieve in the kidney glomerulus, and these cells can be damaged by signals in the blood, including the inflammatory mediator Tumor Necrosis Factor (TNF).

High content imaging or high content screening (HCS), enables fluorescence microscopy to be carried out at scale, in a high-throughput, non-biased manner. Experiments are carried out in multi-well plates, typically 96-wells, meaning that multiple drugs, doses and time points can be assessed in a single plate – making this technique particularly amenable to studying signaling dynamics. This webinar will focus on the development of HCS assays for CKD. Assays to monitor the dynamics of TNF signaling in human kidney podocytes will be explored, together with assays for ER stress and apoptosis in diabetic nephropathy.

Attend this webinar to learn:

  • How high content imaging can be used to monitor intracellular signaling, focusing on chronic kidney disease (inflammation, ER stress and diabetic nephropathy).
  • Tips for developing a good HCS assay for drug development, including what signaling features tend to give a robust read-out.
  • More about the primary cell models being developing for CKD at Newcells Biotech.
A picture of Dr Kathryn Garner
Dr Kathryn Garner
Principal Scientist, Head of Kidney Development, Newcells Biotech